Thrombophilic risk factors in patients with severe carotid atherosclerosis

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 3, 2005, Pages 502-507

  Marcucci, R ^a   Sofi, F ^a   Fedi, S ^a   Lari, B ^a   Sestini, I ^a   Cellai, A P ^a   Pulli, R ^a   Pratesi, G ^a   Pratesi, C ^a   Gensini, G F ^a   Abbate, R ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carotid artery; Gene polymorphisms; Hemostasis; Homocysteine; Lipoprotein(a)

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; LIPOPROTEIN A; PROTHROMBIN; BLOOD CLOTTING FACTOR 5; LUPUS ANTICOAGULANT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HETEROZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOPHILIA; ARTERIOSCLEROSIS; BLOOD; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; ARTERIOSCLEROSIS; CAROTID ARTERY DISEASES; CAROTID STENOSIS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; LUPUS COAGULATION INHIBITOR; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA;

EID: 23944463016     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01173.x     Document Type: Article

References (51)

1. Goldsteine LB, Adams R, Becker K. Primary prevention of ischemic stroke. Stroke 2001; 32: 280-99.
2. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Gronne Nordestgaard B. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100: 3-10.
3. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997; 78: 1430-3.
4. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
5. Franco RF, Trip MD, den Cate H, van den Ende A, Prins MH, Kastelein JJ, Reitsma PH. The 20210 G → A mutation in the 3́-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999; 104: 50-4.
6. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
7. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, Servidei S, Tonali PA, Leone G. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
8. Longstreth WT Jr, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, Raghunathan TE, Koepsell TD, Reitsma PH. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29: 577-80.
9. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
10. Croft SA, Daly ME, Steeds RP, Channer KS, Samani NJ, Hampton KK. The prothrombin 20210A allele and its association with myocardial infarction. Thromb Haemost 1999; 81: 861-4.
11. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, Ardissino D, Palareti G, Bernardi F. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 2418-22.
12. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002.
13. Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke 2000; 31: 1289-93.
14. Ariyo AA, Thach C, Tracy R. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003; 349: 2108-15.
15. Sramek A, Reiber JH, Baak-Pablo R, Sturk A, Rosendaal FR. Lipoprotein(a) and ultrasonographically determined early atherosclerotic changes in the carotid and femoral artery. J Thromb Haemost 2003; 1: 374-9.
16. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck Study. Circulation 1999; 100: 1154-60.
17. Raitakari OT, Adams MR, Celermajer DS. Effect of Lp(a) on the early functional and structural changes of atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19: 990-5.
18. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-9.
19. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995; 273: 1269-73.
20. Schlaich MP, John S, Langenfeld MR, Lackner KJ, Schmilz G, Schmieder RE. Does lipoprotein(a) impair endothelial function? J Am Coll Cardiol 1999; 31: 359-65.
21. Vermuelen EG, Stehouwer CD, Valk J, Van Der Knaap M, Van Der Berg M, Twisk JW, Prevoo W, Rauwerda JA. Effect of homocysleine-lowering treatment with folic acid plus vilamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo-conlrolled randomized trial. Eur J Clin Invest 2004; 34: 256-61.
22. Spence JD, Blake C, Landry A, Fenster A. Measurement of carotid plaque and effect of vitamin therapy for total homocsyteine. Clin Chem Lab Med 2003; 41: 1498-504.
23. Becker A, Henry RM, Kostense PJ, Joakobs C, Teerlink T, Zweegman S, Dekker JM, Nijpels G, Henje RJ, Bouter LM, Smulders YM, Stehouwer CD. Plasma homcosyteine and S-adenosylmethionine in erythrocytes as determinants of carotid intima-media thickness: different effects in diabetic and non-diabetic individuals. The Hoorn Study. Atherosclerosis 2003; 169: 323-30.
24. Demuth K, Drunat S, Girerd X, Moatti N, Paul JL, Safar M, Boutouyrie P. Homocysteine is the only plasma thiol associated with carotid artery remodelling. Atherosclerosis 2002; 165: 167-74.
25. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL. Homocysteine, MTHFR 677C → T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59: 529-36.
26. Sasaki T, Watanabe M, Nagai Y, Hoshi T, Takasawa M, Nukata M, Taguchi A, Kitagawa K, Kinoshita N, Matsumoto M. Association of plasma homocsyteine concentration with atherosclerotic carotid plaques and lacunar infarction. Stroke 2002; 33: 1493-6.
27. Barnett HJ, Meldrum HE, Eliasziw M; North American Symptomatic Carotid Endarterectomy Trial (NASCET) collaborators. The appropriate use of carotid endarterectomy. CMAJ 2002; 166: 1169-79.
28. Chobainian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JRJL, Jones DW, Materson BJ, Oparil S, Wright JJT, Roccella JT. The Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-71.
29. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adult (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
30. 30 Reports of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: S5-S20.
31. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3́-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
32. Balasa VV, Gruppo RA, Glueck CJ, Stroop D, Becker A, Pillow A, Wang P. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 1999; 81: 739-44.
33. Kyrle PA, Mannhalter C, Beguin S, Stumpften A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
34. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995; 75: 12B-17B.
35. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-8.
36. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-12.
37. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer DJ, Horaist C, Hanson SR, Lumsden A, Salam TA. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res 1994; 75: 1029-38.
38. Vouret-Craviari V, Van Obberghen-Schilling E, Rasmussen UB, Pavirani A, Lecocq JP, Pouyssegur J. Synthetic alpha-thrombin receptor peptides activate G protein-coupled signalling pathways but are unable to induce mitogenesis. Mol Biol Cell 1992; 3: 95-102.
39. Okazaki H, Majesky MW, Harker LA, Schwartz SM. Regulation of platelet-derived growth factor ligand and receptor gene expression by alpha-thrombin in vascular smooth muscle cells. Circ Res 1992; 71: 1285-93.
40. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 2003; 12: 302-7.
41. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis? Immunobiology 2003; 207: 13-6.
42. Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11: 208-14.
43. Lam EY, Taylor LM, Landry GJ, Porter JM, Moneta GL. Relationship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity bypass operations. J Vasc Surg 2001; 33: 976-82.
44. Dangas G, Mehran R, Harpel PC, Sharma SK, Marcovina SM, Dube G, Ambrose JA, Fallon JT. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32: 2035-42.
45. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677 CT polymorphism and risk of coronary artery disease: a meta-analysis. JAMA 2002; 288: 2023-31.
46. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet 1998; 351: 263.
47. Marcucci R, Zanazzi M, Bertoni E, Rosati A, Fedi S, Lenti M, Prisco D, Castellani S, Abbate R, Salvadori M. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 2003; 75: 1551-5.
48. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362: 35l-4.
49. Sramek A, Bucciarelli P, Federici AB, Mannucci PM, De Rosa V, Castaman G, Morfini M, Mazzucconi MG, Rocino A, Schaivoni M, Scaraggi FA, Reiber JH, Rosendaal FR. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 2004; 109: 740-4.
50. Tanis BC, Bloemenkamp M, van den Bosch M, Kemmeren JM, Algra A, Van De Graaf Y, Rosendaal FR. Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 2003; 122: 471-8.
51. Hak AE, Polderman KH, Westerdorp IC, Jacobs C, Hofman A, Witterman JC, Stehouwer CD. Increased plasma homocysteine after menopause. Atherosclerosis 2000; 149: 163-8.